- Home
- Publications
- Publication Search
- Publication Details
Title
A patent review of IDO1 inhibitors for cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 28, Issue 4, Pages 317-330
Publisher
Informa UK Limited
Online
2018-02-23
DOI
10.1080/13543776.2018.1441290
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
- (2018) Jae Eun Cheong et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- In silico discovery and therapeutic potential of IDO1 and TDO2 inhibitors
- (2017) Finith E Jernigan et al. Future Medicinal Chemistry
- Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate
- (2017) Stefano Crosignani et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Covalent Kinase Inhibitor from a DNA-Encoded Small-Molecule Library × Protein Library Selection
- (2017) Alix I. Chan et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Targeting TDO in cancer immunotherapy
- (2017) Cheng-Peng Yu et al. MEDICAL ONCOLOGY
- Lessons Learned from Two Decades of Anticancer Drugs
- (2017) Zhichao Liu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
- (2017) Eddy W. Yue et al. ACS Medicinal Chemistry Letters
- Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1
- (2017) Ariel Lewis-Ballester et al. Nature Communications
- Combinatorial approach to cancer immunotherapy: strength in numbers
- (2016) Anna E. Vilgelm et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4
- (2016) Katharina Ochs et al. JOURNAL OF NEUROCHEMISTRY
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Perspectives in Medicinal Chemistry: Metalloprotein Inhibitors: What Have We Made and What is the Next Step?
- (2015) Xing-Xing Zhang et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Metalloprotein Inhibitors for the Treatment of Human Diseases
- (2015) Yang Yang et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
- (2015) Ute F. Röhrig et al. JOURNAL OF MEDICINAL CHEMISTRY
- Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1
- (2015) Yi-Hui Peng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- T cell exclusion, immune privilege, and the tumor microenvironment
- (2015) J. A. Joyce et al. SCIENCE
- Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
- (2015) Ulrike M. Litzenburger et al. Oncotarget
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Crystal Structures and Structure–Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors
- (2014) Shingo Tojo et al. ACS Medicinal Chemistry Letters
- Trial watch: IDO inhibitors in cancer therapy
- (2014) Erika Vacchelli et al. OncoImmunology
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 – 2012)
- (2013) Eduard Dolušić et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Development of a histone deacetylase 6 inhibitor and its biological effects
- (2013) J.-H. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
- (2012) L. Pilotte et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen
- (2011) Jason R. Smith et al. BIOORGANIC & MEDICINAL CHEMISTRY
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
- (2011) Maria T Pallotta et al. NATURE IMMUNOLOGY
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
- (2010) X. Liu et al. BLOOD
- Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism
- (2010) N. T. Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling
- (2010) Brett C. DiNatale et al. TOXICOLOGICAL SCIENCES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now